Fezolinetant (Veozah)

About

Fezolinetant is a neurokinin 3 (NK3) receptor antagonist that is FDA-approved for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause. It represents a novel, non-hormonal treatment option.

Efficacy

Reduces frequency of moderate-to-severe vasomotor symptoms by 65-77% compared to 37-54% with placebo at 12 weeks

Targets Symptoms